Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  MDxHealth  /  MDxHealth nieuws 2014

MDxHealth nieuws 2014

Volgen
5.395 Posts
Pagina: «« 1 ... 81 82 83 84 85 ... 270 »» | Laatste | Omlaag ↓
  3. Pelikapuntzak 1 april 2014 19:50
    3/31/2014 @ 9:19AM
    Exact Sciences Exploits Advances In Colon Cancer Detection
    Comment Now Follow Comments
    In the United States, 50,000 people die from colon cancer each year and 140,000 new cases are reported every year. As cancer goes, colon cancer is second only to lung cancer as the biggest killer in the United States. Fortunately, for the most part, colon cancer is easily preventable because it typically starts as non-cancerous polyps that sometimes develop into cancer over a prior of five to 15 years.

    The gold standard for early polyp detection is colonoscopy. A colonoscopy requires preparation to clean the colon for one to two days. A thin flexible tube with a video camera at the end is inserted into the colon through the rectum. At present guidelines call for regular screening for colon cancer starting at age 50 using both invasive and non-invasive methods. Colonoscopy is an invasive method; non-invasive methods include immunochemical-based fecal occult blood testing (FIT) and guaiac-based fecal occult blood testing (gFOBT). Unfortunately compliance with the guidelines is poor, only about 33% of people over the age of 50 undertake screening. The main reasons are that people simply do not like prepping for colonoscopy and undergoing this invasive procedure, the FIT test is non-invasive but only 74% accurate.

    The Food and Drug Administration (FDA) advisory panel has unanimously recommended approval of a new home test Cologuard developed by Exact Sciences Corporation (EXAS). FDA typically follows the recommendation of the panel.

    By using DNA markers in a lab on stool samples that may be collected at home, Exact Sciences showed in a large study detection of 92% of cancers compared to 74% from the FIT test.

    Obamacare underscored the importance of colon cancer screening by making colonoscopy a required benefit in health insurance policies. If that was not enough, a typical insurance plan covers 100% of the cost of colonoscopy when used for screening irrespective of the deductible in the insurance policy. Not only is Cologuard a major advance in science, it will come to the market at the right time.

    The stock of Exact Sciences fell after the approval. The reason is that Exact Sciences is valued at about $1 billion based on the hopes for Cologuard, but it is difficult to forecast the future revenues of this company. There are some negatives, Cologuard generates about 10% false positive tests, and it detects only 42% of pre-cancerous polyps.

    With colonoscopy being available for free to most Americans; will Cologuard catch on in this age of high deductible insurance policies? Commercial insurers are expected to cover Cologuard but its cost maybe applied to insurance deductible. A person can get a colonoscopy and know with 100% certainty the status of colon without incurring any costs. In comparison, a person may have to spend $300 to $500 on Colonguard and still have lots of uncertainty.

    Another negative is that specialists fearful of litigation may continue to push colonoscopy over Cologuard.

    In the near future, one piece of good news that may help the stock is approval of coverage by the Centers for Medicare and Medicaid Services. Such approval may trigger a jump in the stock.

    Among sell side analysts, there is a big divergence between estimates. For 2015, the high revenue estimate is $239 million and the low estimate is only $60 million. It is easy for bulls to put some big numbers on the table such as $3 billion in sales and $750 million in net income. Such big numbers are easily justifiable. There are 80 million older adults in the U. S. who are potential users of Cologuard; international market is much bigger. If such projections materialize, the stock is dirt cheap. On the other hand, if the test does not catch on, it is conceivable that three years out sales may be only about $200 million. The reality is likely to be to be someplace in the middle.

    It is worth noting that Kevin Conroy, the CEO of the company previously sold Third Wave to Hologic (HOLX). The inference is that he may position Exact Science for a sale.

    Of special note is that 20.06 million shares are short out of a float of 65.24 million. Short ratio is 18.80. These numbers are an indication of the conviction of bears that Cologuard will not become popular. However, this is a perfect set up for a short squeeze. Based on extensive analysis of short squeezes, this set up can easily take the stock to about $25 in a short squeeze. Until there is more clarity it is prudent to consider this stock for trading and not for long term investment.

    One thing is certain; this stock will provide many trading opportunities from both long and short sides. Until there is more clarity, long term investors may simply want to keep this stock on their radar but not jump into it with both feet.

    Follow me here, write me at Nigam@TheAroraReport.com or find me at The Arora Report.

    Disclosure: Subscribers to The Arora Report have a long position in Hologic.
  5. forum rang 4 Diegy 1 april 2014 21:14
    quote:

    Pelikapuntzak schreef op 1 april 2014 18:02:

    Beurshuis Petercam verhoogt het koersdoel MDxhealth naar € 8.50.
    Kan dat bericht nergens vinden. Als dat een leugen is is dat een heel vies spelletje wat je speelt. En zou je eigenlijk een ban moeten krijgen voor mensen op het verkeerde been te zetten met je verhoogde koopadvies. Geen link is een leugen.
  6. [verwijderd] 1 april 2014 21:18
    quote:

    Diegy schreef op 1 april 2014 21:14:

    [...]
    Kan dat bericht nergens vinden. Als dat een leugen is is dat een heel vies spelletje wat je speelt. En zou je eigenlijk een ban moeten krijgen voor mensen op het verkeerde been te zetten met je verhoogde koopadvies. Geen link is een leugen.
    1 april trekt altijd debielen aan ;) Zo`n beetje elk aandeel is vandaag ook al een keer of 2 "overgenomen".
  12. [verwijderd] 2 april 2014 07:42
    Goedemorgen,
    Begin ziet er terug niet goed uit; 6000 aandelen in de aanbieding (markt) is terug proberen het aandeel naar beneden te trekken. Onbegrijpelijk. Ik hoop dat hij eens een koekje van eigen deeg krijgt. Ik denk dat het beste zal zijn, verkopen en later op de dag terugkopen (zie gisteren). Ik hoop ,dat ik ongelijk krijg maar vrees ervoor
  18. [verwijderd] 2 april 2014 08:23
    MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer

    Published: 08:00 CEST 02-04-2014 /GlobeNewswire /Source: MDxHealth (TM) /XBRU: MDXH /ISIN: BE0003844611

    MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer

    IRVINE, CA, and HERSTAL, BELGIUM - April 2, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into a co-marketing agreement with LI PATH (Long Island Pathology, Inc.) to promote MDxHealth's ConfirmMDx® for Prostate Cancer test. LI PATH is a high-end, full-service independent anatomic and clinical pathology laboratory that serves the New York City metropolitan area. The agreement expands MDxHealth's access to urologists in the highly populated New York and New Jersey region.

    "Our goal is to be the premier laboratory serving the urology community in the New York City area, and offering the most advanced molecular testing to our urology clients is an important part of that equation," stated Ken Cerney, Chief Executive Officer of LI PATH. "The ConfirmMDx for Prostate Cancer test provides actionable information to help urologists better stratify patients at risk for undetected prostate cancer and guide the decision for repeat biopsy. The addition ConfirmMDx to our portfolio of tests enhances our ability to serve our clients."

    "We are excited to announce our strategic partnership with LI PATH, recognized as a leading anatomic and clinical pathology laboratory in the New York metropolitan region. With their extensive client base and strong reputation, the partnership further expands access to our ConfirmMDx for Prostate Cancer test within this important geographic region," said Dr. Jan Groen, CEO of MDxHealth. "It is rewarding to partner with progressive thinking laboratory professionals like LI PATH, who are focused on leveraging molecular diagnostic tests to deliver the highest quality patient care."

    About ConfirmMDx® for Prostate Cancer
    Over 975,000 American men receive a negative prostate biopsy result each year, though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with greater than 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples; however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and rule in high-risk patients who may require repeat biopsies and potential treatment.

    About LI PATH
    LI PATH is a premier diagnostic and consultative anatomical laboratory located in East Setauket, New York that has been serving the regional community for nearly 20 years. LI PATH is dedicated to providing top-level diagnostic pathology and clinical services in a cost effective and efficient manner. The laboratory's pathologists are certified by the American Board of Pathology with multiple areas of sub-specialties and are active members of the community. For additional information about LI PATH's clinical and AP diagnostic offerings, please visit www.lipath.com

    About MDxHealth
    MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

    For more information:

    Dr. Jan Groen, CEO
    Mike Sinclair
    Len Hall
    MDxHealth
    Halsin Partners
    Allen & Caron, Inc
    US: +1 949 812 6979
    UK: +44 20 7318 2955
    US: +1 949 474 4300
    BE: +32 4 364 20 70
    Cell: +44 7968 022075
    len@allencaron.com
    info@mdxhealth.com
    msinclair@halsin.com


    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

    NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

    To access the PDF version, please click here

    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. Source: MDxHealth (TM), Tour 5 GIGA niveau +3 Av. de l’Hopital 11, Liège 4000, Belgique
    If you would like to unsubscribe and stop receiving these e-mails click here.
5.395 Posts
Pagina: «« 1 ... 81 82 83 84 85 ... 270 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum